SCHEMBL3284074

SCHEMBL3284074

CCOC(=O)CCCCCCCN

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.83
PAOX Q6QHF9 1/20 0.52
DGKA P23743 1/20 0.52
ALDH1A1 P00352 3/20 0.51
ALOX15 P16050 3/20 0.51
TDP1 Q9NUW8 2/20 0.51
TSHR P16473 2/20 0.51
CYP3A4 P08684 1/20 0.51
HSD17B10 Q99714 1/20 0.51
GAA P10253 2/20 0.50
CPB2 Q96IY4 1/20 0.49
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
PLG P00747 1/20 0.48
LMNA P02545 1/20 0.48
THRB P10828 1/20 0.48
SLC6A2 P23975 1/20 0.48
RECQL P46063 1/20 0.48
SLC6A3 Q01959 1/20 0.48
PAM P19021 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4919758 1.00 CYP1A2 (0.83) CYP1A2PAOXDGKAALDH1A1ALOX15
SCHEMBL1463911 1.00 CYP1A2 (0.83) CYP1A2PAOXDGKAALDH1A1ALOX15
SCHEMBL1471510 1.00 CYP1A2 (0.83) CYP1A2PAOXDGKAALDH1A1ALOX15
SCHEMBL4915851 1.00 CYP1A2 (0.83) CYP1A2PAOXDGKAALDH1A1ALOX15
SCHEMBL4915881 1.00 CYP1A2 (0.83) CYP1A2PAOXDGKAALDH1A1ALOX15
SCHEMBL4915709 1.00 CYP1A2 (0.83) CYP1A2PAOXDGKAALDH1A1ALOX15
SCHEMBL4925671 1.00 CYP1A2 (0.83) CYP1A2PAOXDGKAALDH1A1ALOX15
SCHEMBL2967294 1.00 CYP1A2 (0.83) CYP1A2PAOXDGKAALDH1A1ALOX15
SCHEMBL7547097 1.00 CYP1A2 (0.83) CYP1A2PAOXDGKAALDH1A1ALOX15
SCHEMBL7543573 1.00 CYP1A2 (0.83) CYP1A2PAOXDGKAALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114404424-A A pharmaceutical composition for treating alopecia, and its preparation method 硬核医药科技(上海)有限公司 2022-04-29 CN claimed
CN-108794358-B Substituted benzenesulfonyl compounds and application thereof in preparing medicines 中国人民解放军第二军医大学 2022-08-12 CN disclosed
CN-114404424-A A pharmaceutical composition for treating alopecia, and its preparation method 硬核医药科技(上海)有限公司 2022-04-29 CN disclosed
CN-108794358-A Substitution benzenesulfonyl class compound and its purposes for preparing drug 中国人民解放军第二军医大学 2018-11-13 CN disclosed
CN-101421251-B 4,5-diphenyl-pyrimidinyl-amino substituted carboxylic acids, method for the production and use thereof as medicaments SANOFI AVENTIS DEUTSCHLAND 2011-10-19 CN disclosed
US-7713988-B2 4,5-diphenyl-pyrimidinylamino substituted carboxylic acids, method for the production and use thereof as medicaments SANOFI-AVENTIS (FR) 2010-05-11 US disclosed
US-20090149487-A1 4,5-DIPHENYL-PYRIMIDINYLAMINO SUBSTITUTED CARBOXYLIC ACIDS, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS SANOFI-AVENTIS (FR) 2009-06-11 US disclosed
CN-101421251-A 4,5-diphenyl-pyrimidinyl-amino substituted carboxylic acids, method for the production and use thereof as medicaments SANOFI AVENTIS DEUTSCHLAND (FR) 2009-04-29 CN disclosed
US-20080167418-A1 Method for Producing an Aqueous Polyamide Dispersion BASF AKTIENGESELLSCHAFT (DE) 2008-07-10 US disclosed
US-20080132674-A1 Method for the Production of an Aqueous Polymer Dispersion BASF AKTIENGESELLSCHAFT (DE) 2008-06-05 US disclosed
US-4136180-A HYPOLIPIDEMIC SUBSTITUTED STYRENESULFONYLUREAS PFIZER INC. (US) 1979-01-23 US disclosed
US-4062960-A Hypolipidemic alkenesulfonamides PFIZER INC. (US) 1977-12-13 US disclosed
US-3983107-A ARTERIOSCLEROSIS PFIZER INC. (US) 1976-09-28 US disclosed
US-3957607-A Process for the preparation of lipide soluble complexes of cations, application of the process and use of the complexes W. MOLLER GLASBLASEREI (CH) 1976-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149487-A1 4,5-DIPHENYL-PYRIMIDINYLAMINO SUBSTITUTED CARBOXYLIC ACIDS, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS GPR119, DPP4, SLC5A1 CYP1A2 1216/4885PAOX 119/4885DGKA 2308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.